keyword
MENU ▼
Read by QxMD icon Read
search

Yttrium-90

keyword
https://www.readbyqxmd.com/read/28812136/clinical-outcomes-of-y90-radioembolization-for-recurrent-hepatocellular-carcinoma-following-curative-resection
#1
Rehan Ali, Ahsun Riaz, Ahmed Gabr, Nadine Abouchaleh, Ronald Mora, Ali Al Asadi, Juan Carlos Caicedo, Michael Abecassis, Nitin Katariya, Haripriya Maddur, Laura Kulik, Robert J Lewandowski, Riad Salem
PURPOSE: To assess safety/efficacy of yttrium-90 radioembolization (Y90) in patients with recurrent hepatocellular carcinoma (HCC) following curative surgical resection. METHODS: With IRB approval, we searched our prospectively acquired database for patients that were treated with Y90 for recurrent disease following resection. Baseline characteristics and bilirubin toxicities following Y90 were evaluated. Intention-to-treat overall survival (OS) and time-to-progression (TTP) from Y90 were assessed...
August 15, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28781171/first-line-selective-internal-radiotherapy-plus-chemotherapy-versus-chemotherapy-alone-in-patients-with-liver-metastases-from-colorectal-cancer-foxfire-sirflox-and-foxfire-global-a-combined-analysis-of-three-multicentre-randomised-phase-3-trials
#2
Harpreet S Wasan, Peter Gibbs, Navesh K Sharma, Julien Taieb, Volker Heinemann, Jens Ricke, Marc Peeters, Michael Findlay, Andrew Weaver, Jamie Mills, Charles Wilson, Richard Adams, Anne Francis, Joanna Moschandreas, Pradeep S Virdee, Peter Dutton, Sharon Love, Val Gebski, Alastair Gray, Guy van Hazel, Ricky A Sharma
BACKGROUND: Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with colorectal liver metastases with liver-dominant disease after chemotherapy. The FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised studies evaluated the efficacy of combining first-line chemotherapy with SIRT using yttrium-90 resin microspheres in patients with metastatic colorectal cancer with liver metastases. The studies were designed for combined analysis of overall survival...
August 3, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28767473/acquired-hemophilia-a-after-hepatic-yttrium-90-radioembolization-a-case-report
#3
Susanna Tribuzi, Alessia Naccarato, Lorella Pelagalli, Marco Covotta, Giulia Torregiani, Claudia Claroni, Ester Forastiere
Acquired hemophilia is a rare but potentially life-threatening bleeding disorder caused by the development of autoantibodies (inhibitors) directed against plasma coagulation factors, most frequently factor VIII. We report a case of a 65-year-old man with hepatocellular carcinoma who bled massively after a hepatic Yttrium-90 radioembolization procedure (Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres [SIRTex]). An acquired deficiency of factor VIII was diagnosed and successfully treated with recombinant activated factor VII and immunosuppression...
August 1, 2017: A & A Case Reports
https://www.readbyqxmd.com/read/28758319/treatment-options-for-unresectable-hcc-with-a-focus-on-sirt-with-yttrium-90-resin-microspheres
#4
REVIEW
Eric A Wang, Jeff P Stein, Ross J Bellavia, Scott R Broadwell
Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, is the second leading cause of cancer-related deaths across the globe. Only a small percentage of HCC patients (~20%-30%) are diagnosed at an early stage when first-line treatment options may be effective. The majority of HCC patients (>70%) are diagnosed with unresectable disease and given a poor overall prognosis. Current treatment guidelines recommend locoregional therapy with transarterial chemoembolisation (TACE) and systemic therapy with sorafenib as first-line treatment for patients with intermediate and advanced stage HCC...
July 30, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28740906/the-development-commercialization-and-clinical-context-of-yttrium-90-radiolabeled-resin-and-glass-microspheres
#5
REVIEW
Mark A Westcott, Douglas M Coldwell, David M Liu, Joseph F Zikria
Selective internal radiation therapy has emerged as a well-accepted therapeutic for primary and metastatic hepatic malignancies. This therapeutic modality requires the combined efforts of multiple medical disciplines to ensure the safe delivery of yttrium-90 ((90)Y)-labeled microspheres. The development of this therapy followed decades of clinical research involving tumor vascularity and microsphere development. Today, it is essential that treating physicians have a thorough understanding of hepatic tumor vascularity and (90)Y microsphere characteristics before undertaking this complex intervention...
October 2016: Advances in Radiation Oncology
https://www.readbyqxmd.com/read/28736649/neoadjuvant-transarterial-radiation-lobectomy-for-colorectal-hepatic-metastases-a-small-cohort-analysis-on-safety-efficacy-and-radiopathologic-correlation
#6
Jehan L Shah, Ivan R Zendejas-Ruiz, Linday M Thornton, Brian S Geller, Joseph R Grajo, Amy Collinsworth, Thomas J George, Beau Toskich
Colorectal cancer patients have a high incidence of liver metastasis (ml-CRC). Surgical resection is the gold standard for treatment of hepatic metastasis but only a small percent of patients are traditional candidates based on disease extent and adequate size of the future liver remnant (FLR). Interventions such as portal vein embolization (PVE) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) are performed to increase FLR for operative conversion. Limitations to PVE include intrahepatic disease progression, portal vascular invasion, and utilization with concurrent chemotherapy...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28700244/targeted-yttrium-89-doxorubicin-drug-eluting-bead-a-safety-and-feasibility-pilot-study-in-a-rabbit-liver-cancer-model
#7
Johannes M Ludwig, Minzhi Xing, Yongkang Gai, Lingyi Sun, Dexing Zeng, Hyun S Kim
The purpose of this article is to evaluate feasibility and safety of the cancer targeting (radio)-chemoembolization drug-eluting bead (TRCE-DEB) concept drug SW43-DOX-L-NETA((89)Y) DEB for the intra-arterial treatment of VX2 rabbit liver tumors. The treatment compound comprises of the sigma-2 receptor ligand SW43 for cancer targeting, doxorubicin (DOX), and (89)yttrium ((89)Y) as nonradioactive surrogate for therapeutic (yttrium-90, lutetium-177) and imaging (yttrium-86) radioisotopes via the chelator L-NETA...
August 7, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28689934/single-center-comparison-of-overall-survival-and-toxicities-in-patients-with-infiltrative-hepatocellular-carcinoma-treated-with-yttrium-90-radioembolization-or-drug-eluting-embolic-transarterial-chemoembolization
#8
Joseph L McDevitt, Ali Alian, Baljendra Kapoor, Stacy Bennett, Amanjit Gill, Abraham Levitin, Mark Sands, K V Narayanan Menon, Federico N Aucejo, Bassam Estfan, Anil K Pillai, Sanjeeva P Kalva, Gordon McLennan
PURPOSE: To compare overall survival and toxicities after yttrium-90 ((90)Y) radioembolization and chemoembolization with drug-eluting embolics (DEE) in patients with infiltrative hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Retrospective review of 50 patients with infiltrative HCC without main portal vein invasion who were treated with (90)Y radioembolization (n = 26) or DEE chemoembolization (n = 24) between March 2007 and August 2012 was completed...
July 6, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28685382/safety-and-efficacy-of-transarterial-radioembolisation-in-patients-with-intermediate-or-advanced-stage-hepatocellular-carcinoma-refractory-to-chemoembolisation
#9
Elisabeth G Klompenhouwer, Raphaëla C Dresen, Chris Verslype, Annouschka Laenen, Gert De Hertogh, Christophe M Deroose, Lawrence Bonne, Vincent Vandevaveye, Geert Maleux
INTRODUCTION: Transarterial chemoembolisation (TACE) is the most widely used locoregional treatment for patients with an unresectable hepatocellular carcinoma (HCC). Transarterial radioembolisation (TARE) with yttrium-90 containing microspheres is an emerging interventional treatment that could be complementary or an alternative to TACE. AIM: To evaluate the safety and efficacy of TARE in patients with HCC who are refractory to TACE with drug-eluting beads (DEB-TACE)...
July 6, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28677067/intra-arterial-therapy-of-neuroendocrine-tumour-liver-metastases-comparing-conventional-tace-drug-eluting-beads-tace-and-yttrium-90-radioembolisation-as-treatment-options-using-a-propensity-score-analysis-model
#10
Duc Do Minh, Julius Chapiro, Boris Gorodetski, Qiang Huang, Cuihong Liu, Susanne Smolka, Lynn Jeanette Savic, David Wainstejn, MingDe Lin, Todd Schlachter, Bernhard Gebauer, Jean-François Geschwind
OBJECTIVES: To compare efficacy, survival outcome and prognostic factors of conventional transarterial chemoembolisation (cTACE), drug-eluting beads TACE (DEB-TACE) and yttrium-90 radioembolisation (Y90) for the treatment of liver metastases from gastroenteropancreatic (GEP) neuroendocrine tumours (NELM). METHODS: This retrospective analysis included 192 patients (58.6 years mean age, 56% men) with NELM treated with cTACE (N = 122), DEB-TACE (N = 26) or Y90 (N = 44) between 2000 and 2014...
July 4, 2017: European Radiology
https://www.readbyqxmd.com/read/28674968/recommendations-for-radioembolisation-after-liver-surgery-using-yttrium-90-resin-microspheres-based-on-a-survey-of-an-international-expert-panel
#11
Morsal Samim, Linde M van Veenendaal, Manon N G J A Braat, Andor F van den Hoven, Richard Van Hillegersberg, Bruno Sangro, Yung Hsiang Kao, Dave Liu, John D Louie, Daniel Y Sze, Steven C Rose, Daniel B Brown, Hojjat Ahmadzadehfar, Edward Kim, Maurice A A J van den Bosch, Marnix G E H Lam
INTRODUCTION: Guidelines on how to adjust activity in patients with a history of liver surgery who are undergoing yttrium-90 radioembolisation ((90)Y-RE) are lacking. The aim was to study the variability in activity prescription in these patients, between centres with extensive experience using resin microspheres (90)Y-RE, and to draw recommendations on activity prescription based on an expert consensus. METHODS: The variability in activity prescription between centres was investigated by a survey of international experts in the field of (90)Y-RE...
July 3, 2017: European Radiology
https://www.readbyqxmd.com/read/28673658/long-term-hepatotoxicity-of-yttrium-90-radioembolization-as-treatment-of-metastatic-neuroendocrine-tumor-to%C3%A2-the%C3%A2-liver
#12
Yu-Kai Su, Rosewell V Mackey, Ahsun Riaz, Vanessa L Gates, Al B Benson, Frank H Miller, Vahid Yaghmai, Ahmed Gabr, Riad Salem, Robert J Lewandowski
PURPOSE: To determine long-term hepatotoxicity of yttrium-90 ((90)Y) radioembolization in patients treated for metastatic neuroendocrine tumor (mNET) and evaluate if imaging and laboratory findings of cirrhosis-like morphology are associated with clinical symptoms. MATERIALS AND METHODS: Retrospective review from 2003 to 2016 was performed for patients with mNET treated with (90)Y glass microspheres. Fifty-four patients with > 2 year follow-up were stratified into unilobar (n = 15) vs whole-liver (n = 39) treatment...
June 30, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28668402/comparative-study-of-post-transplant-outcomes-in-hepatocellular-carcinoma-patients-treated-with-chemoembolization-or-radioembolization
#13
Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Michael Vouche, Rohi Atassi, Khairuddin Memon, Ali Al Asadi, Talia Baker, Juan Carlos Caicedo, Kush Desai, Jonathan Fryer, Ryan Hickey, Michael Abeccassis, Ali Habib, Elias Hohlastos, Daniel Ganger, Laura Kulik, Robert J Lewandowski, Ahsun Riaz, Riad Salem
PURPOSE: To analyze long-term outcomes in patients bridged/downstaged to orthotopic liver transplantation (OLT) by transarterial chemoembolization (TACE) or yttrium-90 radioembolization (Y90) for hepatocellular carcinoma (HCC). METHODS: 172 HCC patients who underwent OLT after being treated with transarterial liver-directed therapies (LDTs) (Y90: 93; TACE: 79) were identified. Pre-LDT and pre-OLT clinical/imaging/laboratory characteristics including United Network for Organ Sharing (UNOS) staging and alpha-fetoprotein values (AFP) were tabulated...
August 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28653161/the-post-sir-spheres-surgery-study-p4s-retrospective-analysis-of-safety-following-hepatic-resection-or-transplantation-in-patients-previously-treated-with-selective-internal-radiation-therapy-with-yttrium-90-resin-microspheres
#14
Fernando Pardo, Bruno Sangro, Rheun-Chuan Lee, Derek Manas, Rohan Jeyarajah, Vincent Donckier, Geert Maleux, Antonio D Pinna, Lourens Bester, David L Morris, David Iannitti, Pierce K Chow, Richard Stubbs, Paul J Gow, Gianluca Masi, Kevin T Fisher, Wan Y Lau, Konstantinos Kouladouros, Georgios Katsanos, Giorgio Ercolani, Fernando Rotellar, José I Bilbao, Michael Schoen
BACKGROUND: Reports show that selective internal radiation therapy (SIRT) may downsize inoperable liver tumors to resection or transplantation, or enable a bridge-to-transplant. A small-cohort study found that long-term survival in patients undergoing resection following SIRT appears possible but no robust studies on postsurgical safety outcomes exist. The Post-SIR-Spheres Surgery Study was an international, multicenter, retrospective study to assess safety outcomes of liver resection or transplantation following SIRT with yttrium-90 (Y-90) resin microspheres (SIR-Spheres(®); Sirtex)...
June 26, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28652100/current-role-for-radioisotope-synovectomy
#15
Vincent André, Vincent Dalibard, Emmanuelle Dernis, Stéphane Varin, Grégoire Cormier
Radioisotope synovectomy has been extensively used to treat patients with chronic inflammatory joint disease but has moved to a less prominent position since the introduction of new and highly effective drugs. Remaining indications are refractory synovitis, pigmented villonodular synovitis as an adjunct to surgery, and hemophilic arthropathy. The three main radioisotopes used are yttrium-90, rhenium-186, and erbium-189. Radioisotope synovectomy should be performed only by highly experienced professionals, to minimize the risk of injection-related complications...
June 23, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/28651746/the-management-of-colorectal-liver-metastases
#16
B Maher, E Ryan, M Little, P Boardman, B Stedman
Colorectal cancer remains a leading cause of cancer-related death in Europe. Approximately one-quarter of patients have synchronous hepatic metastases and metachronous liver metastases occur in a further 30%. The scope of surgery in management of colorectal metastases has evolved to include selected patients with extra-hepatic disease for whom R0 resection is considered feasible; however, locoregional treatments are increasingly recognised as viable management options in those patients deemed unsuitable for surgery and there is an expanding body of evidence regarding their ability to achieve local control and increase progression-free survival in the liver...
August 2017: Clinical Radiology
https://www.readbyqxmd.com/read/28643982/-current-surgical-treatment-for-hepatocellular-carcinoma-critical-appraisal-of-current-guidelines
#17
Daniel Clerc, Nermin Halkic, Nicolas Demartines, Emmanuel Melloul
Hepatocellular carcinoma (HCC) management has evolved in the last decades. Current available treatments include interventional radiology like radiofrequency ablation, transarterial chemoembolization or Yttrium 90 radioembolization. Surgery, when possible, has been proven to be the most effective treatment in reducing the risk of long-term local recurrence. American and European societies (AASLD, EASL, respectively) guidelines for the management of HCC endorse The Barcelona Clinic Liver Cancer (BCLC) treatment allocation system...
June 14, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28634672/hcc-locoregional-therapies-yttrium-90-y-90-selective-internal-radiation-therapy-sirt
#18
REVIEW
İsa Burak Güney
No abstract text is available yet for this article.
June 21, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28634669/yttrium-90-y-90-resin-microsphere-therapy-for-patients-with-unresectable-hepatocellular-carcinoma-a-single-center-experience
#19
Semra İnce, Bülent Karaman, Engin Alagoz, Nuri Karadurmuş, Hüseyin Şan, Cemal Nuri Erçin, Nuri Arslan
BACKGROUND/AIM: Selective intraarterial radionuclide therapy (SIRT) with yttrium-90 (Y-90) resin microspheres presently has successful results in primary or metastatic inoperable liver tumors. This procedure, which is also known as radioembolisation, delivers high doses of radiation selectively to hepatic tumors while minimum healthy liver exposure. The aim of this study was to present our clinical experience of radiomicrosphere therapy for the treatment of patients with unresectable hepatocellular carcinoma (HCC)...
June 20, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28624008/a-systematic-review-of-yttrium-90-radioembolization-for-unresectable-liver-metastases-of-melanoma
#20
REVIEW
Zhongzhi Jia, Guomin Jiang, Chunfu Zhu, Kai Wang, Shaoqin Li, Xihu Qin
PURPOSE: To assess the effectiveness of yttrium-90 ((90)Y) radioembolization in the treatment of unresectable liver metastases of melanoma. METHODS: PubMed and EMBASE were systemically searched for all English language studies related to (90)Y radioembolization for unresectable liver metastases of melanoma, including clinical trials, observational studies, and abstracts from conferences, published between January 1991 and March 2016. RESULTS: A total of 12 reports (7 observational studies and 5 abstracts from conferences) involving 255 patients were included in the analysis...
July 2017: European Journal of Radiology
keyword
keyword
33486
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"